Hagens Berman says GRAIL investors face Aug. 4 lead-plaintiff deadline in fraud suit
Hagens Berman says a securities fraud class action has been filed against GRAIL, Inc., and that investors who bought shares during a stated class period have until August 4, 2026, to seek lead-plaintiff status.
Hagens Berman Sobol Shapiro LLP said Friday that a securities fraud class action has been filed against GRAIL, Inc. The firm said investors who bought GRAIL common stock between May 13, 2025, and Feb. 19, 2026, may seek appointment as lead plaintiff by Aug. 4, 2026.
The law firm’s alert says the case centers on GRAIL’s Feb. 19, 2026, announcement of top-line results from its NHS-Galleri trial. It says GRAIL shares fell 50.55% in one trading session, from a Feb. 19 close of $101.53 to $50.21 on Feb. 20, 2026, and that more than $2.2 billion in market value was erased.
Hagens Berman said it is investigating when GRAIL and its management first recognized that the follow-up period needed for the trial diverged from the three-year duration it says the company had touted.
The alert identifies Reed Kathrein as the partner leading the investigation. In a quoted statement included in the release, Kathrein said the firm is focused on when GRAIL and its management knew the need for a longer follow-up period diverged from the touted three-year duration.
The alert says investors who purchased or acquired GRAIL common stock during the stated period and suffered significant losses may ask the court to appoint them as lead plaintiff. It also says whistleblowers with non-public information about GRAIL may consider the SEC whistleblower program, which can reward original information with up to 30% of any successful SEC recovery.
Hagens Berman published the alert on July 31, 2026. The firm’s notice does not include a response from GRAIL, and the research brief provided to Atlas did not include one.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()